{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-109714","form_type":"8-K","ticker":"PMN","cik":"0001374339","company_name":"ProMIS Neurosciences Inc.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.251374+00:00","generated_at":"2026-05-16T20:59:19.399000+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ProMIS Neurosciences reports Q3 2025 results; Phase 1b AD trial over 85% enrolled","bullets":["Cash $15.4M at Sep 30, 2025, up from $13.3M at Dec 31, 2024; raised ~$21.6M in July 2025.","Phase 1b PRECISE-AD trial over 85% enrolled; Cohorts 1 and 2 fully enrolled.","DSMB unanimously recommended proceeding to third dose cohort; interim data Q2 2026, top-line Q4 2026.","Operating loss $11.8M for Q3 2025 vs $4.4M in Q3 2024, driven by increased R&D on PMN310 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-109714","json":"https://secwatch.observer/filing/0001104659-25-109714.json","markdown":"https://secwatch.observer/filing/0001104659-25-109714.md","text":"https://secwatch.observer/filing/0001104659-25-109714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/0001104659-25-109714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1374339/000110465925109714/pmn-20251112x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:59:19.399000+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}